{"id":41473,"date":"2023-11-20T01:31:52","date_gmt":"2023-11-20T07:31:52","guid":{"rendered":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/s0819-pub\/"},"modified":"2023-11-20T01:31:52","modified_gmt":"2023-11-20T07:31:52","slug":"s0819-pub","status":"publish","type":"tcia_citation","link":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/s0819-pub\/","title":{"rendered":"S0819-PUB"},"template":"","class_list":["post-41473","tcia_citation","type-tcia_citation","status-publish"],"tcia_citation_type":"Publication Citation","tcia_citation_text":"<p><span><span><span>Herbst, R. S., Redman, M. W., Kim, E. S., Semrad, T. J., Bazhenova, L., Masters, G., Oettel, K., Guaglianone, P., Reynolds, C., Karnad, A., Arnold, S. M., Varella-Garcia, M., Moon, J., Mack, P. C., Blanke, C. D., Hirsch, F. R., Kelly, K., &amp; Gandara, D. R. (2018). <strong>Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.<\/strong> In The Lancet Oncology (Vol. 19, Issue 1, pp. 101\u2013114). Elsevier BV.<\/span> <a href=\"https:\/\/doi.org\/10.1016\/s1470-2045(17)30694-0\">https:\/\/doi.org\/10.1016\/s1470-2045(17)30694-0<\/a>.<\/span> Epub 2017 Nov 20.<\/span>\u00a0<\/p>\n","tcia_citation_statement":"","tcia_citation_doi":"10.1016\/s1470-2045(17)30694-0","_links":{"self":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations\/41473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations"}],"about":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/types\/tcia_citation"}],"wp:attachment":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/media?parent=41473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}